Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 464

1.

Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.

Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D.

Appl Health Econ Health Policy. 2013 Oct;11(5):485-97. doi: 10.1007/s40258-013-0047-8.

PMID:
23868102
2.

Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.

Parthan A, Kruse M, Agodoa I, Silverman S, Orwoll E.

Bone. 2014 Feb;59:105-13. doi: 10.1016/j.bone.2013.11.002.

PMID:
24231131
3.

Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium.

Hiligsmann M, Reginster JY.

Pharmacoeconomics. 2011 Oct;29(10):895-911. doi: 10.2165/11539980-000000000-00000.

PMID:
21692551
4.

Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.

Chau D, Becker DL, Coombes ME, Ioannidis G, Adachi JD, Goeree R.

J Med Econ. 2012;15 Suppl 1:3-14. doi: 10.3111/13696998.2012.737393.

PMID:
23035625
5.
6.

Health-economic comparison of three recommended drugs for the treatment of osteoporosis.

Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.

Int J Clin Pharmacol Res. 2004;24(1):1-10.

PMID:
15575171
7.

Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.

Ström O, Jönsson B, Kanis JA.

Osteoporos Int. 2013 Apr;24(4):1491-502. doi: 10.1007/s00198-012-2115-6.

PMID:
23224141
8.

Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.

Tosteson AN, Burge RT, Marshall DA, Lindsay R.

Am J Manag Care. 2008 Sep;14(9):605-15.

9.

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.

Jönsson B, Ström O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, Kanis JA.

Osteoporos Int. 2011 Mar;22(3):967-82. doi: 10.1007/s00198-010-1424-x.

10.

Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.

Berto P, Maggi S, Noale M, Lopatriello S.

Aging Clin Exp Res. 2010 Apr;22(2):179-88. doi: 10.3275/6816.

PMID:
20145427
11.

Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.

Hiligsmann M, Reginster JY.

Bone. 2010 Jul;47(1):34-40. doi: 10.1016/j.bone.2010.03.009.

PMID:
20303422
12.

Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.

Goeree R, Blackhouse G, Adachi J.

Curr Med Res Opin. 2006 Jul;22(7):1425-36.

PMID:
16834841
13.
14.

The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.

Murphy DR, Smolen LJ, Klein TM, Klein RW.

BMC Musculoskelet Disord. 2012 Oct 30;13:213. doi: 10.1186/1471-2474-13-213.

15.

The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis.

Thompson M, Pasquale M, Grima D, Moehrke W, Kruse HP.

Value Health. 2010 Jan-Feb;13(1):46-54. doi: 10.1111/j.1524-4733.2009.00666.x.

16.

The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.

Fleurence RL, Iglesias CP, Johnson JM.

Pharmacoeconomics. 2007;25(11):913-33. Review.

PMID:
17960951
17.

Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.

Hiligsmann M, Bruyère O, Reginster JY.

Bone. 2010 Feb;46(2):440-6. doi: 10.1016/j.bone.2009.08.052.

PMID:
19716940
18.

Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective.

Silverman S, Agodoa I, Kruse M, Parthan A, Orwoll E.

J Osteoporos. 2015;2015:627631. doi: 10.1155/2015/627631.

19.
20.

Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.

Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, Qian Y, Dansey R, Chung K.

J Med Econ. 2012;15(4):712-23. doi: 10.3111/13696998.2012.675380.

PMID:
22409231

Supplemental Content

Support Center